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Vascular remodeling underlies the pathogenesis of major cardiovascular diseases and involves degradation and 
reorganization of the extracellular matrix of the vessel wall. 
Elastin is the major component of elastic fibers and represents 
one of the main structural matrix components of the vascu-
lar wall together with collagens. This highly stable molecule 
with longevity comparable to human lifespan1–3 is essential for 
maintaining the strength, resilience, and integrity of the vessel 
wall.4–6 Local inflammation concurrently with increased elas-
tase activity, calcium, and lipid deposits are typical features of 
physiological and pathological vascular aging that contribute 
to elastin degradation.7–11
Elastin degradation releases bioactive elastin-derived peptides 
(EDP) known as elastokines. Among them, peptides harboring 
the GxxPG motif, such as the canonical VGVAPG peptide, have 
been shown to act on several cells, such as endothelial cells, 
monocytes, and smooth muscle cells.8 Most of their effects have 
been assigned to their interaction with the elastin receptor com-
plex (ERC). The ERC is a singular membrane receptor composed 
of 3 subunits: a peripheral 67-kDa subunit called elastin-binding 
protein (EBP), a 55-kDa protective protein/cathepsin A (PPCA), 
and a 61-kDa neuraminidase (Neuraminidase-1, Neu-1).12
Considered for a long time as a mechanical support for cells, 
the extracellular matrix and its degradation products are now 
regarded as important regulators of cell physiology and devel-
opment of vascular diseases. Accumulating evidence in the 
literature suggest that EDP may play important roles in the pro-
gression of age-related vascular diseases. For instance, a proath-
erogenic role of EDP has been recently described in ApoE−/− and 
LDLR−/− mice.13 In addition, chronic accumulation of EDP has 
been shown to promote hyperglycemia and insulin resistance in 
mice.14 Vascular aging is also associated with hemostasis dysreg-
ulation and increased thrombosis tendency.15 However, the effect 
of EDP on thrombosis has never been studied to date.
In this study, we investigated the role of EDP in platelet 
aggregation and thrombus formation in vitro and in vivo using 
both human and mouse whole blood. We show for the first 
time that EDP regulate thrombosis by an original mechanism 
© 2014 American Heart Association, Inc.
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Objective—Elastin is the major structural extracellular matrix component of the arterial wall that provides the elastic recoil 
properties and resilience essential for proper vascular function. Elastin-derived peptides (EDP) originating from elastin 
fragmentation during vascular remodeling have been shown to play an important role in cell physiology and development 
of cardiovascular diseases. However, their involvement in thrombosis has been unexplored to date. In this study, we 
investigated the effects of EDP on (1) platelet aggregation and related signaling and (2) thrombus formation. We also 
characterized the mechanism by which EDP regulate thrombosis.
Approach and Results—We show that EDP, derived from organo-alkaline hydrolysate of bovine insoluble elastin (kappa-
elastin), decrease human platelet aggregation in whole blood induced by weak and strong agonists, such as ADP, epinephrine, 
arachidonic acid, collagen, TRAP, and U46619. In a mouse whole blood perfusion assay over a collagen matrix, kappa-elastin 
and VGVAPG, the canonical peptide recognizing the elastin receptor complex, significantly decrease thrombus formation 
under arterial shear conditions. We confirmed these results in vivo by demonstrating that both kappa-elastin and VGVAPG 
significantly prolonged the time for complete arteriole occlusion in a mouse model of thrombosis and increased tail bleeding 
times. Finally, we demonstrate that the regulatory role of EDP on thrombosis relies on platelets that express a functional 
elastin receptor complex and on the ability of EDP to disrupt plasma von Willebrand factor interaction with collagen.
Conclusions—These results highlight the complex nature of the mechanisms governing thrombus formation and reveal an 
unsuspected regulatory role for circulating EDP in thrombosis.  (Arterioscler Thromb Vasc Biol. 2014;34:2570-2578.)
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involving effects both at the platelet level and at the matrix 
level by competing for von Willebrand factor (vWF) immobi-
lization on collagen. At the platelet level, we further demon-
strate the existence of a functional ERC that is able to decrease 
washed platelet aggregation and to regulate thrombus forma-
tion in vitro and in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
EDP Decrease Human Platelet Aggregation 
and αIIbβ3 Activation in Whole Blood
The effects of EDP on platelet aggregation were first inves-
tigated in whole blood by impedance aggregometry with the 
Multiplate® analyzer. As shown in Figure 1, kappa-elastin 
(kE) significantly decreased platelet aggregation induced by 
weak (ADP, epinephrine, arachidonic acid) and strong (col-
lagen, TRAP, U46619) platelet agonists. At 100 μg/mL kE, 
whole blood platelet aggregations were inhibited by ≈20%, 
48%, and 36% for ADP, epinephrine, and arachidonic acid, 
respectively, and by 35%, 25%, and 45% for collagen, TRAP, 
and U46619, respectively (Figure 1A and 1B).
We next evaluated the effects of kE on αIIbβ3 activation and 
CD62P surface exposure by flow cytometry. At resting state, 
kE had no effect on the activation level of αIIbβ3, P-selectin 
(CD62P), and phosphatidylserine surface expression (Figure I 
in the online-only Data Supplement) and did not trigger tyrosine 
phosphorylation of platelet proteins (Figure II in the online-only 
Data Supplement). In collagen-, TRAP-, and ADP-activated 
platelets, 100 μg/mL kE significantly decreased αIIbβ3 acti-
vation by 41.3%±8.8%, 46.3%±5.7%, and 37.1%±6.9%, 
respectively (Figure 1C). In contrast, no effect was observed 
on platelet granule secretion induced by collagen, TRAP, and 
ADP, as evidenced by anti-CD62P binding levels (Figure 1D).
Taken together, these data indicate that EDP affect platelet 
function in whole blood by decreasing both platelet aggre-
gation and activation of αIIbβ3 without modifying platelet 
secretion. Importantly, when used alone, kE has no effect on 
platelet viability and activation.
EDP and VGVAPG Reduce Thrombus 
Formation In vitro Under Flow Conditions
The effects of EDP on platelet interaction with collagen under 
flow conditions were assessed using a whole blood perfusion 
assay over a fibrillar collagen matrix at 1500/s. As shown in 
Figure 2B, preincubation of mouse whole blood with 100 
μg/mL kE significantly decreased the area covered by plate-
lets from 60 seconds of perfusion. At 150 seconds, the inhi-
bition reached 43% in the presence of kE (12.9%±2.2%) 
compared with control (22.8%±2.1%). To examine whether 
the ERC can reduce thrombus formation in vitro, we used 
the canonical VGVAPG peptide. This peptide was used at a 
4-fold higher concentration than kE (400 μg/mL) because it 
has been demonstrated that a 4-fold higher concentration is 
necessary to achieve the equivalent physiological stimulation 
levels of bioactive elastin peptides released after elastin degra-
dation.13,14,16 As negative control, a scrambled VVGPGA pep-
tide was used.17,18 As shown in Figure 2A and 2C, VGVAPG 
significantly decreased the area covered by platelets from 30 
seconds of perfusion. At 150 seconds of perfusion, VGVAPG 
decreased by 30% the area covered by platelets compared 
with scrambled peptide (27.0%±3.7% versus 38.7%±4.5%).
All these data demonstrate that EDP and VGVAPG reduce 
thrombus formation in vitro and suggest the likely contribu-
tion of the ERC in this process.
EDP Disrupt Plasma vWF 
Immobilization Onto Collagen
Platelet interaction with collagen under flow conditions 
requires the initial rolling and slowing down of platelets 
through vWF immobilized onto collagen. We therefore inves-
tigated if part of the inhibitory effects observed in Figure 2 
could be explained by disruption of vWF immobilization onto 
collagen. Increasing concentrations of kE (25–200 μg/mL) 
significantly decreased mouse and human plasma vWF bind-
ing to immobilized collagen (Figure 3A and 3B). The maxi-
mal effect was observed at 100 μg/mL kE with 77.9%±7.1% 
and 87.0%±5.0% inhibition for mouse and human, respec-
tively. Although statistically significant, VGVAPG decreased 
slightly mouse plasma vWF binding to immobilized colla-
gen compared with kE. At 400 μg/mL, the inhibition was of 
12.7%±2.3% (Figure 3C). No effect was observed for human 
plasma (Figure 3D). We next evaluated whether EDP could 
directly interact with vWF or collagen. Although both human 
and mouse plasma vWF did not interact with immobilized 
kE (Figure 3E), soluble kE dose-dependently interacted with 
immobilized collagen (Figure 3F).
Taken together, these data indicate that EDP, but not 
VGVAPG, are able to disrupt plasma vWF immobilization 
onto collagen by interacting with collagen and thereby com-
peting for vWF binding.
VGVAPG Directly Affects Human Platelet 
Aggregation and Related Signaling
As the inhibitory effects of the VGVAPG peptide suggested 
the contribution of the ERC in platelets, we evaluated whether 
this peptide could inhibit collagen-induced washed platelet 
aggregation and related signaling. As shown in Figure 4A, 
washed platelet aggregation induced by 1 μg/mL collagen was 
significantly decreased by VGVAPG (63.9%±12.0%) com-
pared with scrambled peptide (100.9%±5.4%). Comparable 
inhibition was reached at 100 μg/mL kE (Figure 4A). Platelet 
Nonstandard Abbreviations and Acronyms
EBP elastin-binding protein
ECM extracellular matrix
EDP elastin-derived peptides
ERC elastin receptor complex
kE kappa-elastin
Neu-1 neuraminidase-1
PPCA protective protein/cathepsin A
vWF von Willebrand factor
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aggregation was stopped 180 seconds after the addition of 
collagen by adding sodium dodecyl sulfate. Probing for tyro-
sine-phosphorylated proteins showed that collagen activation 
increased the phosphorylation pattern of platelet proteins 
(Figure 4B and 4C). kE and VGVAPG seem to affect these 
phosphorylations as evidenced by densitometry analysis of a 
BA
DC
w/
o
+k
E 2
5
+k
E 5
0
+k
E 1
00
+k
E 2
00
0
100
200
300
400
500
600
***
****
*
AU
C
 (A
U
*m
in
)
w/
o
+k
E 2
5
+k
E 5
0
+k
E 1
00
+k
E 2
00
0
100
200
300
400
*
**
AU
C
 (A
U
*m
in
)
w/
o
+k
E 2
5
+k
E 5
0
+k
E 1
00
+k
E 2
00
0
100
200
300
400
500
600
***
***
AU
C
 (A
U
*m
in
)
w/
o
+k
E 2
5
+k
E 5
0
+k
E 1
00
+k
E 2
00
0
100
200
300
400
500
*
**
AU
C
 (A
U
*m
in
)
w/
o
+k
E 2
5
+k
E 5
0
+k
E 1
00
+k
E 2
00
0
100
200
300
400
500
**
**
AU
C
 (A
U
*m
in
)
w/
o
+k
E 2
5
+k
E 5
0
+k
E 1
00
+k
E 2
00
0
100
200
300
400
500
600
700
800
900
** ***
AU
C
 (A
U
*m
in
)
Figure 1. Elastin-derived peptides decrease human platelet aggregation and activation of αIIbβ3 in whole blood but not CD62P surface 
exposure. A and B, Platelet aggregation was measured in whole blood using the Multiplate® analyzer. Whole blood was incubated with 
saline buffer containing different concentrations of kE (25–200 μg/mL). Platelet aggregation was induced by (A) 0.32 μg/mL Horm col-
lagen, 32 μM TRAP, or 0.5 μM U46619, or by (B) 6.5 μM ADP, 0.25 mmol/L arachidonic acid, or 10 μM epinephrine, and monitored for 
6 minutes. Results were expressed as AUC of arbitrary units (AU min) and compared with control (w/o, without kE). Data represent the 
mean±SEM of 3 to 11 independent experiments. *P<0.05; **P<0.01; ***P<0.001. C and D, Activation of αIIbβ3 and surface exposure of 
CD62P were determined by flow cytometry with FITC–conjugated PAC-1 (C) and anti-CD62P (D) antibody, respectively. Whole blood 
was incubated with 50 or 100 μg/mL kE and stimulated, or not, by 20 μg/mL Horm collagen, 10 μM TRAP, or 20 μM ADP for 5 minutes 
at 37°C without stirring to prevent platelet aggregation. Data represent the mean fluorescent intensity (MFI)±SEM of 3 to 5 independent 
experiments normalized to control without kE. *P<0.05; **P<0.01.
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protein migrated at ≈65 kDa (Figure 4B and 4C). Its phos-
phorylation level was significantly decreased by kE and 
VGVAPG compared with their respective control (Figure 4C).
Taken together, these results indicate that a functional ERC 
is present on platelets and is able to directly modulate platelet 
aggregation and related signaling.
EBP, Neu-1, and PPCA Are Expressed in 
Platelets and Form a Functional ERC
The Neu-1 subunit has been shown to play a critical role 
in ERC-mediated effects.19 On binding of EDP to the EBP 
subunit, Neu-1 catalyzes the local conversion of GM3 gan-
glioside into lactosylceramide as a result of its sialidase 
activity.19 We checked for the presence of Neu-1 and PPCA 
in both human and mouse platelets by western blotting. Both 
ERC subunits were detected in human and mouse platelet 
lysates (Figure 5A and 5B). Overall, the migration patterns 
were similar between the 2 species with the exception of 
PPCA, suggesting differences in posttranslational modifica-
tions. Because of the unavailability of selective antibodies to 
detect EBP, we were unable to demonstrate the presence of 
EBP at the protein level. We therefore checked at the mRNA 
level in human megakaryocytes and normalized the expres-
sion to GAPDH. As shown in Figure 5D, EBP, Neu-1, and 
PPCA transcripts were unambiguously expressed in 2 differ-
ent human megakaryoblastic cell lines (CHRF-288-11 and 
MEG-01) and in human CD34+ hematopoietic stem cells at 
6 and 11 days after in vitro differentiation.20 Similar results 
were observed when normalizing to another housekeeping 
gene, RPL32 (Figure 5E). To confirm the functionality of 
the receptor in human platelets, nonpermeabilized washed 
platelets were incubated with 100 μg/mL kE, and sialidase 
activity was assessed using the 2-O-(p-nitrophenyl)-α-d-N-
acetylneuraminic acid as substrate. After 2 hours of incu-
bation, kE significantly increased by 50.4%±3.0% sialidase 
activity in platelets (Figure 5C).
Together, these results demonstrate that EBP, Neu-1, and 
PPCA are well expressed in platelets and form a functional 
receptor able to trigger activation of its Neu-1 subunit.
EDP and VGVAPG Delay Thrombosis In Vivo
The effects of kE were finally investigated in in vivo throm-
bosis using the FeCl3-induced mesenteric arteriole thrombo-
sis model. Ten minutes before the induction of thrombosis 
by 10% FeCl3, mice were intravenously injected with 10 mg/
kg kE or vehicle.14 The time for the formation of a stable 
occlusive thrombus was significantly prolonged in kE-treated 
mice compared with vehicle-injected control mice (37.4±5.1 
minutes versus 22.8±2.8 minutes, respectively; P=0.022; 
Figure 6A and 6B). To examine whether binding of VGVAPG 
to the ERC also delays thrombosis in vivo, mice were injected 
with VGVAPG (40 mg/kg) and compared with scrambled 
VVGPGA. As shown in Figure 6C, injection of VVGPGA 
increased by ≈2-fold the time to complete occlusion com-
pared with saline-injected mice (Figure 6B), suggesting that 
this scrambled peptide had some unexpected effects in this 
model as in the in vitro model of thrombus formation wherein 
the scrambled peptide increased the area covered by platelets 
compared with saline (Figure 2B and 2C). However, when 
compared with VGVAPG-treated mice, occlusion times were 
significantly longer in these mice (75.3±2.7 minutes versus 
50.5±4.7 minutes, respectively; P=0.001; Figure 6C), sug-
gesting that binding of VGVAPG to the ERC can regulate in 
vivo thrombosis.
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Figure 2. Elastin-derived peptides and VGVAPG impair platelet interaction with collagen under flow conditions. The effects of elastin-
derived peptides on platelet interaction with collagen were investigated in a whole blood perfusion assay over a Horm collagen matrix 
at 1500/s. Mouse whole blood was collected in 40 μM PPACK and 5 U/mL low-molecular-weight heparin, incubated with saline buffer, 
kE (100 μg/mL), VGVAPG (400 μg/mL), or VVGPGA (400 μg/mL) together with rhodamine 6G (10 μg/mL) for 5 minutes at 37°C and per-
fused for 180 seconds. A, The progression of platelet adhesion and thrombi formation was observed under an epifluorescent micro-
scope (representative of 4 experiments). B and C, Results were expressed as the mean percentage of area covered by platelets±SEM 
from 4 independent experiments. B, kE (gray bars) vs saline buffer (black bars); C, VGVAPG (gray bars) vs scrambled VVGPGA (black 
bars). *P<0.05; **P<0.01; ***P<0.001.
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Together, these observations strongly indicate that circulat-
ing EDP affects thrombus formation in vivo and that the ERC 
is an important regulator in this process. The effects of EDP 
and VGVAPG were then evaluated in a tail-bleeding assay 
and bleeding times for kE- (707±17 seconds) and VGVAPG- 
(593±52 seconds) treated mice were significantly longer than 
those for saline- (360±40 s) and VVGPGA- (413±51 s) treated 
mice (Figure 6D). However, 33% of VVGPGA-treated mice 
showed no cessation of bleeding in the observed time period 
in contrast to 11% for VGVAPG-treated mice. Therefore, 
additional experiments are required to definitively prove that 
the ERC is involved in the regulation of tail bleeding time.
Discussion
EDP originating from elastin fragmentation are one of the 
major products of extracellular matrix degradation released 
during vascular aging. Generation of EDP is a typical feature 
of inflamm-aging8 and correlates with occurrence of vascular 
stiffness, calcification, and lipid deposits.9–11,21,22 A growing 
body of evidences now suggests that these extracellular matrix 
degradation products can also affect adjacent/circulating cells 
and contribute to the progression of age-associated vascular 
diseases.21,23 In this context, we recently demonstrated that 
chronic injection of EDP in mice potentiates atherosclerosis 
development and promotes insulin resistance,14,24 2 events that 
mainly occur during aging.
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Figure 3. Elastin-derived peptides disrupt plasma vWF/collagen interaction by specifically interacting with collagen. Mouse (A and C) or 
human (B and D) plasma (1/200) were added for 2 hours at 37°C in collagen-coated wells (25 μg/mL) previously incubated with different con-
centrations of (A and B) kE (25–200 μg/mL) or (C and D) VGVAPG (200 or 400 μg/mL). Bound vWF was revealed by a horseradish peroxidase–
coupled rabbit anti-human vWF antibody. Results are expressed are mean±SEM of 4 to 6 independent experiments, each run in triplicate, and 
normalized to the control (w/o, without kE). E, Mouse or human plasma (1/200) were added for 2 hours at 37°C in kE-coated wells (100 μg/mL) 
and bound vWF was revealed as above. Results are expressed are mean±SEM of 9 experiments, each run in triplicate, and normalized to their 
corresponding control (mean binding of human or mouse plasma vWF to collagen). F, Increasing concentrations of kE (25–100 μg/mL) were 
added for 2 hours at 37°C in collagen-coated wells (25 μg/mL). Bound elastin-derived peptides were revealed by the BA4 antibody followed by 
a horseradish peroxidase-coupled anti-mouse secondary antibody. Results are expressed as mean±SEM of 3 independent experiments, each 
run in triplicate, and normalized to the control (w/o, without kE). *P<0.05; **P<0.01; ***P<0.001; NS, nonsignificant.
 at BU Reims Champagne Ardenne on November 20, 2014http://atvb.ahajournals.org/Downloaded from 
Kawecki et al  Elastin-Derived Peptides Regulate Thrombosis  2575
Human blood concentrations of EDP reported in the liter-
ature fluctuate tremendously according to the method used 
for EDP assay.25–28 However, blood EDP production has 
been shown to increase with the progression of various vas-
cular diseases, such as in atherosclerosis, aneurysms, and 
chronic kidney disease.22,26,28 For instance, serum EDP con-
centration in patients with chronic kidney disease at stages 
3 and 4 has been measured at 57 μg/mL ranging from 43 to 
78 μg/mL.22 In wild-type C57Bl/6J male mice, blood EDP 
concentration was estimated at 7.7±1.1 mg/kg culminating 
at 14.2±1.1 mg/kg in high fat diet mice and 15.2±1.2 mg/kg 
in diabetic (db/db) mice.14 Importantly, local concentrations 
of EDP at the site of injury are predicted to be even higher. 
Indeed, a specific feature of locally produced EDP is to 
increase further the elastolytic activity by acting on infiltrat-
ing cells at the site of vascular injury. This higher elastolytic 
activity will further increase elastin degradation and release 
of large amounts of EDP. This phenomenon is referred to as 
a self-propelled vicious circle, which could contribute to the 
progression and chronicity of vascular disease.21
In this study, we investigated the effects of EDP in thrombo-
sis, another age-related vascular disease. We took advantage 
of kE, widely used for a long time for research and industrial 
purposes. kE is a complex mixture of EDP that contains bio-
active peptides harboring the GxxPG motif recognized by the 
ERC. By combining both in vitro and in vivo approaches, 
we demonstrated that circulating EDP regulate thrombosis 
and hemostasis by an original mechanism involving effects 
both at the platelet and at the matrix levels. At the platelet 
level, EDP were shown to significantly decrease human 
platelet aggregation in whole blood induced by several ago-
nists, such as collagen, TRAP, U46619, ADP, epinephrine, 
and arachidonic acid, with a maximal inhibition culminating 
at 20% to 48% according to the agonist used. This inhibi-
tory effect was associated with decreased αIIbβ3 activation, 
suggesting that binding of EDP to platelets may affect the 
inside-out signaling pathways leading to αIIbβ3 activation. 
No effect was, however, observed on α-granule secretion as 
evidenced by measuring CD62P binding to platelets in whole 
blood on agonist challenge. Because of the complex nature 
of kE, we systematically used the VGVAPG peptide versus a 
scrambled peptide (VVGPGA) in the following experiments 
to specifically focus on the ERC in these processes because 
this peptide is known to bind specifically to the EBP subunit 
of this receptor.29,30 Indeed, ≈29 different peptides were iden-
tified in kE mixtures by mass spectrometry analysis with one 
third containing the bioactive GxxPG motif (not shown).14 
In contrast, the scrambled VVGPGA is unable to adopt the 
type VIII β-turn conformation because of the lack of GxxPG 
motif.30 However, previous studies have reported that simple 
proline-containing peptides, such as PG, WP, and PGP (puta-
tive fragments of collagen and elastin), possess significant 
antithrombotic and anticoagulant effects in vitro and in vivo.31 
This probably explains that the scrambled peptide used in the 
current study had some effects on platelets (Figure 4C) and 
on in vitro (Figure 2C) and in vivo (Figure 6) experiments. 
Other scrambled peptides (GGVVAP, VGVGAP, GAGVVP, 
AVPVGG) were tested and showed similar effects (data not 
shown).
Using washed platelets, we next demonstrated that kE and 
the ERC directly affect platelet function by decreasing col-
lagen-induced platelet aggregation and related signaling. We 
show here that the level of collagen-induced tyrosine phos-
phorylation is significantly reduced by kE and VGVAPG 
as evidenced by decrease of the tyrosine phosphorylation 
of a 65-kDa platelet protein that remains to be identified 
in further studies. Importantly, when tested alone, kE did 
not induce neither platelet activation nor platelet secretion 
or exposure of phosphatidylserine, suggesting that kE did 
not cause desensitization of platelets or affect platelet via-
bility over the time course of the in vitro experiments. The 
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Figure 4. Elastin-derived peptides and VGVAPG decrease colla-
gen-induced aggregation of washed platelets and related protein 
tyrosine phosphorylations. Washed human platelets (3.108/mL) 
were incubated with saline buffer, kE (50 or 100 μg/mL), VGVAPG 
(400 μg/mL), or VVGPGA (400 μg/mL) peptide for 3 minutes at 
37°C. A, Washed platelet aggregation was induced by 1 μg/mL 
Horm collagen and monitored by measuring light transmission 
using a SODEREL aggregometer. Results were expressed as 
percent of aggregation and normalized to control. Data represent 
the mean±SEM of 7 to 8 independent experiments. B, At 180 
seconds after the addition of collagen, platelet aggregates were 
solubilized and proteins separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis. Tyrosine-phosphorylated pro-
teins were detected using the monoclonal anti-phosphotyrosine 
antibody PY20 and the amount of proteins loaded was evaluated 
by a polyclonal anti-actin antibody. A representative tyrosine 
phosphorylation pattern is shown. C, Quantification of the tyrosine 
phosphorylation level of a platelet protein of ≈65 kDa (indicated by 
an arrow on panel B) by densitometry analysis (pTyr/actin ratio). 
Results are expressed as mean±SEM of 3 independent experi-
ments, each run in duplicate, and normalized to nonactivated 
platelets (NA). *P<0.05; **P<0.01; ***P<0.001; NS, nonsignificant.
 at BU Reims Champagne Ardenne on November 20, 2014http://atvb.ahajournals.org/Downloaded from 
2576  Arterioscler Thromb Vasc Biol  December 2014
existence of a functional ERC in platelets was further dem-
onstrated by the presence of both Neu-1 and PPCA in human 
and mouse platelets at the protein level and of EBP, Neu-1, 
and PPCA in human megakaryocytes at the mRNA level. 
These 3 subunits form a functional receptor in human plate-
lets that is able to trigger an increase in sialidase activity on 
binding to EDP. In contrast to PPCA, the catalytic activity 
of Neu-1 has been shown to be essential for ERC-mediated 
effects both in vitro19,32 and in vivo13,14 by catalyzing the local 
conversion of GM3 ganglioside into lactosylceramide.19,32 
Expression of Neu-1 and PPCA has been already reported 
in platelets. Neu-1 has been shown to be up-regulated at 
the cell surface after refrigeration and to participate in vWF 
receptor (GPIbα) desialylation.33 PPCA has been shown to 
be secreted on platelet aggregation,34 but its role in platelet 
activation remains unknown to date. Unfortunately, because 
of the unavailability of anti-EBP antibodies, we were unable 
to demonstrate the presence of EBP at the protein level in 
platelets. However, the increase in platelet sialidase activity 
triggered by EDP confirm that EBP is well present at the 
protein level in platelets.
Deciphering the influence of EDP and the VGVAPG peptide 
on platelet interaction with collagen under flow conditions led 
to the unexpected finding that EDP also disrupt immobiliza-
tion of human and mouse plasma vWF onto collagen fibers as 
a result of a high affinity of EDP for collagen. Indeed, at 25 
μg/mL that represents 0.33 μmol/L (average molecular weight 
of kE=75 kDa), a strong inhibition of 45% was observed with 
a maximal effect culminating at 80% to 85% inhibition. In our 
conditions, both human and mouse plasma vWF were unable 
to interact with immobilized kE as already reported by Matsui 
et al35 and VGVAPG was without effect, suggesting that lon-
ger EDP seem to be involved in disruption of plasma vWF 
immobilization onto collagen.
Specific involvement of EDP in regulating thrombosis and 
hemostasis was finally confirmed in vivo because kE pro-
longed mesenteric arteriole occlusion and tail-bleeding time 
in mice. kE was used at 10 mg/kg, a concentration slightly 
above the blood EDP concentration measured in wild-type 
mice (7.7±1.1 mg/kg) and well below the concentrations esti-
mated in high fat diet (14.2±1.1 mg/kg) and diabetic (15.2±1.2 
mg/kg) mice.14 Importantly, injection of the VGVAPG pep-
tide prolonged mesenteric arteriole occlusion and may also 
increase tail-bleeding time in mice, confirming the specific 
involvement of the ERC in vivo and most probably of the 
ERC-mediated effects described here on platelets. This is fur-
ther strengthened because the VGVAPG peptide has no major 
effect on vWF binding to collagen.
In conclusion, the current study demonstrates for the 
first time that EDP originating from elastin fragmentation 
during vascular aging may be involved in the regulation of 
thrombosis and hemostasis in vivo. It now remains to clar-
ify the contribution of endogenous EDP in murine models 
harboring the pathophysiological features of vascular aging 
because healthy vessels are devoid of atherosclerotic plaques 
and do not recapitulate all the steps and players involved 
in the complex process of thrombus formation at sites of 
atherosclerotic lesions. In addition, these antithrombotic 
A B
D
C
E
WB: pAb anti-Neu1
55
70
100
130
40
35
kDa
WB: pAb anti-PPCA
55
70
100
130
40
35
kDa
26
0.00
0.05
0.10
0.15
0.20
0.25
0.30
EBP
β-Gal
Neu-1
PPCA
1/
∆C
t (
R
PL
32
)
0.00
0.05
0.10
0.15
0.20
0.25
0.30
EBP
β-Gal Neu-1
PPCA
1/
∆C
t (
G
A
PD
H
)
w/
o kE
0
20
40
60
80
100
120
140
160 ***
N
or
m
al
iz
ed
 s
ia
lid
as
e 
ac
tiv
ity
Figure 5. EBP, Neu-1, and PPCA are expressed in platelets and form a functional receptor. Western blot of human and mouse washed 
platelet lysates (25 μg) probed with a rabbit polyclonal (A) anti-Neu-1 or (B) anti-PPCA antibody. Data are representative of 4 independent 
experiments. C, Sialidase activity was measured in nonpermeabilized washed platelets (6.107/well) after 2 hours of incubation at 37°C in 
the presence of 200 μM 2-O-(p-nitrophenyl)-α-d-N-acetylneuraminic acid substrate together with vehicle or kE (100 μg/mL, final concen-
tration). Results are expressed as mean±SEM of 6 independent experiments, each run in triplicate, and normalized to the control (w/o, 
without kE); ***P<0.001. D and E, RT-qPCR analysis of mRNA levels of EBP, β-Gal, Neu-1, and PPCA in the CHRF-288-11 (black bars) 
and MEG-01 (white bars) human megakaryoblastic cell lines and human CD34+ hematopoietic stem cells at 6 (hatched bars) and 11 (gray 
bars) days after in vitro differentiation. mRNA levels were normalized to (D) GAPDH or (E) RPL32 mRNA levels. Data are expressed as 
relative expression (1/ΔCt). EBP indicates elastin-binding protein and PPCA, protective protein/cathepsin A.
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effects of EDP may have deleterious consequences on ath-
erosclerosis progression because intraplaque hemorrhage 
has been associated with increased risk of plaque rupture. 
In this study, we further demonstrated that the regulatory 
role of EDP on thrombosis rely on an original mechanism 
that involves both EDP-mediated disruption of vWF immo-
bilization onto collagen fibers at the matrix level (receptor-
independent) and EDP-mediated effects at the platelet level, 
leading to decreased aggregation and increase in sialidase 
activity. Importantly, platelets express a functional ERC that 
is able to recapitulate the effects observed with kE. However, 
whether EDP and the VGVAPG peptide are acting by the 
same mechanism on platelets remains to be elucidated. 
Indeed, the hypothesis that EDP may also regulate platelet 
function by a receptor-independent mechanism cannot be 
totally discarded. Anyway, this study demonstrates for the 
first time that a functional ERC is present in platelets. On 
binding to an elastin-derived bioactive GxxPG peptide, such 
as VGVAPG, the ERC is able to decrease washed platelet 
aggregation and related signaling and to prolong arteriole 
occlusion and tail-bleeding time. Because the signaling 
pathways mediated by the ERC have been shown to trans-
duce signals through the catalytic activity of its Neu-1 sub-
unit,13,14,36 this study opens new avenues in the complexity of 
the platelet signaling pathways involved during thrombosis 
and hemostasis and offers the exciting possibility of a poten-
tial fine-tuning of platelet receptor sialylation and activation 
by the ERC.
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This is the first study establishing the importance of elastin-derived peptides, proteolysis products of the vascular extracellular matrix (ECM), in the 
regulation of hemostasis and thrombosis. Vascular aging is associated with extensive ECM remodeling leading to the production of ECM-derived 
peptides, known as matrikines, which present new biological activities. These ECM-derived peptides therefore represent promising pharmaceuti-
cal targets. Elastin is a good example of such vascular ECM macromolecules subject to proteolysis. However, the impact of elastin-derived pep-
tides on thrombosis and hemostasis is yet underestimated to date. In this study, we show that elastin-derived peptides regulate thrombosis by an 
original mechanism involving effects both (1) on platelets, that express a functional elastin receptor complex, by reducing platelet aggregation, and 
impairing related signaling and (2) at the matrix level by disrupting plasma von Willebrand factor immobilization onto collagen.
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Supplemental Figure I. Incubation of whole blood with EDP has not effect on platelet αIIb3 
activation, CD62P and PS surface exposure. 
Activation of platelet αIIb3 and surface exposure of P-selectin (CD62P) and 
phosphatidylserine (PS) were determined by flow cytometry with FITC-conjugated PAC-1 
(A), anti-CD62P (B) antibodies, and FITC-conjugated Annexin V (C), respectively. Whole 
blood was incubated with 50, 100 or 200µg/mL kE for 5 minutes at 37°C before acquisition. 
(A,B) For positive controls, see Figure 1. (C) As positive control, whole blood was incubated 
for 5 minutes at 37°C with the calcium ionophore A23187 (10µM). (A,B) Data represent the 
mean fluorescent intensity (MFI) ± SEM of 3 to 5 independent experiments normalized to 
saline buffer (without kE, w/o). (C) Data represent the percentage of CD41+ cells positive for 
Annexin V labeling and are mean ± SEM of 3 independent experiments. *** P< 0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure II. Incubation of washed platelets with EDP has no effect on platelet 
protein tyrosine phosphorylations.  
Washed human platelets (3.108/mL) were incubated with saline buffer or kE (100µg/mL) for 
0, 1, 3, 5 and 10 minutes at 37°C with stirring in the cuvette of an aggregometer. As positive 
control (T+), washed platelets were activated by 10µM TRAP. Then platelets were solubilized 
and proteins separated by SDS-PAGE. Tyrosine phosphorylated proteins were detected 
using the monoclonal anti-phosphotyrosine antibody PY20 and the amount of proteins 
loaded was evaluated by a polyclonal anti-actin antibody. A representative tyrosine 
phosphorylation pattern, of four independent experiments, is shown.  
 
 
MATERIALS AND METHODS 
 
Reagents and antibodies 
Horm collagen was purchased from Nycomed. ADP and TRAP-6 (thrombin receptor 
activating peptide-6) were obtained as Multiplate® reagents from Roche Diagnostics. The 
thromboxane analog U46619 was from Tocris. Rhodamine 6G, apyrase, prostaglandin E1 
(PGE1), ferric chloride, epinephrine, MTT assay, mouse monoclonal anti-phosphotyrosine 
(PY20) and goat polyclonal anti-actin antibodies were from Sigma. Arachidonic acid was 
purchased from Bio/Data Corporation. D-Phe-Pro-Arg chloromethylketone dihydrochloride 
(PPACK) was from Calbiochem. Enoxaparin (2000 UI anti-Xa/0,2 mL) was used as low 
molecular weight heparin (LMWH). The peptides VGVAPG and VVGPGA were synthesized 
by GeneCust (purity >98%). HRP-coupled polyclonal rabbit anti-human von Willebrand factor 
(vWF) antibody was from Dako. The FITC-coupled mouse PAC-1 and anti-CD62P 
antibodies, and FITC-Annexin V were from BD Biosciences. Rabbit polyclonal anti-Neu-1 (H-
300) antibody was from Santa Cruz Biotechnology and anti-PPCA kindly provided by Pr 
Alessandra d'Azzo. The mouse monoclonal BA4 antibody was a kind gift of Pr Robert P 
Mecham. This antibody has been shown to recognize EDP containing the GxxPG motif and 
to be well suitable for enzyme-linked immunosorbent assay.1-3 HRP-coupled anti-rabbit and 
anti-mouse IgG were from Cell Signaling 
 
Kappa-elastin preparation 
EDP were prepared as described previously.4 Briefly, insoluble elastin was prepared from 
bovine ligamentum nuchae by hot alkali treatment. Purity was assessed by comparing its 
amino acid composition to the one predicted from the elastin gene product. Soluble EDP 
were then obtained from insoluble elastin as described.4 The obtained mixture of EDP, 
termed kappa-elastin (kE), has been shown to contain several peptides harboring the 
bioactive motifs PGAIPG, GAVPG, GVLPG, GGVPG, GVVPG, and VGVAPG5. The 
composition of EDP from kE was recently compared to EDP obtained after proteolysis of 
human elastin by neutrophil elastase by mass spectrometry analysis and shown to contain 
similar peptides harboring the bioactive GxxPG motif.5 In addition, kE has been shown to 
exhibit the same biological properties than elastin hydrolysates obtained by human neutrophil 
elastase as both EDP mixtures increase pro-MMP1 production in human skin fibroblasts with 
comparable extent.6 
 
Animals and treatment 
Mouse experiments were performed in agreement with the European legislation on care and 
use of laboratory animals and were approved by the ethical committee of Reims Champagne 
Ardenne. C57Bl/6J male mice of 4 to 6 week-old were purchased from Janvier and 
maintained under standard laboratory conditions for 2 weeks before experiments. 
 
Platelet aggregation in whole blood  
Whole blood was obtained by venipuncture from consenting healthy human donors and 
anticoagulated with sodium citrate (0.129M) using Vacutainer® tubes. Whole blood 
aggregation was monitored by impedance aggregometry at 37°C with stirring using the 
Multiplate® analyzer. Whole blood was diluted in physiological saline (1:1) and incubated with 
different concentrations of kE for 3 minutes at 37°C before adding Horm collagen 
(0.32µg/mL), TRAP (32µM), U46619 (0.5µM), ADP (6.5µM), arachidonic acid (0.25mM), or  
epinephrine (10µM). Curves were recorded for 6 minutes and platelet aggregation was 
determined as area under the curve (AUC) of arbitrary units (AU*min).  
 
Washed platelet aggregation 
Human whole blood was anticoagulated with acid-citrate-dextrose (trisodium citrate 22g/L, 
citric acid 8g/L, dextrose 24.5g/L). Platelet-rich plasma (PRP) was obtained by centrifuging 
whole blood for 15 minutes at 170g at room temperature. Platelets were obtained from PRP 
by centrifugation for 15 minutes at 1200g and washed in the presence of apyrase (0.3U/mL) 
and PGE1 (100nM) to minimize platelet activation. Then platelets were adjusted to 3.108/mL 
in pH 7.5 Tyrode’s buffer (137mM NaCl, 2.7mM KCl, 1.2mM NaHCO3, 0.36mM NaH2PO4 , 
2mM CaCl2, 1mM MgCl2, 5mM HEPES, 5.5mM glucose). Aggregation was monitored by 
measuring light transmission using an 8-channel SODEREL aggregometer. 
 
Flow cytometry analysis 
Ninety five µL of whole blood were incubated for 5 minutes with 5µL of kE (final 
concentrations of 0, 50 and 100µg/mL). Then, the mixtures were incubated, or not, for 5 
minutes with 100µL of agonists (20µg/mL collagen, 20µM ADP or 10µM TRAP, final 
concentrations) then stopped by 250µL of PBS. Twenty µL of each mixture were incubated 
with FITC-PAC1 or FITC-anti-CD62P antibody for 20 minutes at room temperature in 
darkness. Each mixture was then diluted in 1mL PBS and immediately analyzed with a 
FC500 flow cytometer (Coulter). Platelet population was gated using their forward and side 
scatter characteristics. Acquisition and processing data from 5,000 platelets were performed 
and analyzed using CXP software (Coulter). Mean Fluorescent Intensity (MFI) of the whole 
platelet population was used. For FITC-Annexin V labelling, the same protocol was used in 
the presence of Annexin V binding buffer. Platelets were labelled with PE-CD41 and 
acquisition and processing data from 10,000 platelets (CD41+ population) were performed 
and analyzed as mentioned above.   
 
In vitro thrombus formation under flow conditions 
Thrombus formation was evaluated in a whole blood perfusion assay under arterial shear 
condition (1500s-1) over collagen-coated microchannels. Vena8 FLUORO+ biochips (Cellix) 
were coated with Horm collagen (30µg/mL, overnight, 4°C). Whole blood was collected from 
the vena cava of anesthetized mice in 40µM PPACK and 5U/mL LMWH.7 Blood from 2 mice 
were pooled, labeled with rhodamine 6G (10µg/mL) together with vehicle, kE (100µg/mL), 
VGVAPG or scrambled VVGPGA (400µg/mL), and incubated at 37°C for 5 minutes before 
use to resensitize platelets. For all experiments, mouse blood was used within 1 hour. 
Recruitment of platelets and real time thrombus formation was recorded with an 
epifluorescent microscope (Zeiss AX10) connected to a Nikon digital DXM1200 camera. 
Thrombus formation was determined as the mean percentage of total area covered by 
platelets using the ImageJ software.  
 
Collagen binding assay of vWF 
Plasma was obtained from anticoagulated human and mouse blood after centrifugation at 
2,000g for 10 minutes. Ninety six-well microtiter plates (FluoroNunc MaxiSorp, Nunc) were 
coated overnight at 4°C with 25µg/mL Horm collagen diluted in PBS containing 25mM acetic 
acid and then blocked with 1% BSA. Plates were incubated with different concentrations of 
kE (1h, 37°C) followed by mouse or human plasma (1/200) for additional 2 hours at 37°C. 
After washings, bound vWF was detected using HRP-coupled rabbit anti-human vWF 
antibodies (1/2,000). Vizualization was obtained with TMB-ELISA (ThermoScientific) and the 
reaction was stopped with 2M H2SO4. Binding of vWF to collagen in the presence of various 
concentrations of kE was compared to the binding in the absence of kE (normalized at 
100%).  
 
Collagen binding assay of kE 
The same protocol was used as described above, except that bound EDP were detected 
using the BA4 monoclonal antibody (1/10,000) followed by HRP-coupled anti-mouse IgG 
(1/1,000).  
 
kE binding assay of vWF 
Ninety six-well microtiter plates were coated overnight at 4°C with kE (100µg/mL) diluted in 
PBS and then blocked with 1% BSA. Plasma (1/200) was added for 2 hours at 37°C and 
bound vWF was detected as described above. Binding of human and mouse vWF to kE was 
compared to the average binding of human and mouse vWF to collagen, respectively, 
normalized at 100%.  
 
Immunoblotting 
For the detection of Neu-1 and PPCA, human and mouse washed platelets were prepared by 
centrifugation of anticoagulated whole blood at 700g for 15 minutes. The supernatant was 
recovered and platelets were pelleted by centrifugation at 1200g for 15 minutes. Platelets 
were then washed 2 times with washing buffer (36mM citric acid, 5mM glucose, 5mM KCl, 
1mM MgCl2, 103mM NaCl). Washed platelets were lysed in Laemmli buffer, heated at 100°C 
for 5 minutes and subjected to SDS-PAGE. Proteins were then transferred on a nitrocellulose 
membrane (Whatman GmbH). After saturation, membranes were incubated with rabbit 
polyclonal anti-Neu-1 (1/500) or anti-PPCA (1/1,000) overnight at 4°C. Immunoreactive 
bands were revealed using a HRP-conjugated anti-rabbit IgG (1/10,000) followed by 
enhanced chemiluminescence detection reagents (Amersham) and visualized with the 
Odyssey Fc LI-COR scanner (ScienceTec).  
For the analysis of protein tyrosine phosphorylations, washed platelets were lysed by SDS 
2% directly in the cuvette of the aggregometer. Samples were then diluted in Laemmli buffer, 
heated at 100°C for 5 minutes and subjected to SDS-PAGE. Platelet proteins phosphorylated 
on tyrosine residues were revealed using the monoclonal PY20 antibody followed by HRP-
conjugated anti-mouse IgG (1/10,000).  
 
PCR and real-time qRT-PCR 
Total mRNAs were extracted with the Qiagen kit (RNeasy mini kit) from differentiated CD34+ 
human stem cells8 and two human megakaryoblastic cell lines (CHRF-288-11 and MEG-01). 
The RT-qPCR primers for detection of EBP, -Gal and PPCA were designed as previously 
described.9 The forward and reverse primers for Neu-1 were TCCAAGGCTGAGAACGACTT 
and AGGTGTCCACTGAGCCGAT, respectively. All genes were normalized to the human 
housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or ribosomal 
protein L32 (RPL32). The forward and reverse primers for GAPDH were 
CCATCACCATCTTCCAGGAG and CCTGCTTCACCACCTTC, respectively. The forward 
and reverse primers for RPL32 were CATTGGTTATGGAAGCAACAAA and 
TTCTTGGAGGAAACATTGTGAG, respectively. All primers were synthesized by 
Eurogentec.  
One µg of total RNA were reverse-transcribed using the M-MLV reverse transcriptase 
(Invitrogen) according to the manufacturer’s protocol. Real-time PCR was performed using 
an Absolute SYBR Green Rox mix (Thermo Fisher Scientific), on a CFX 96 real time PCR 
detection system (Bio-Rad). PCR conditions were 15 min at 95 °C, followed by 40 cycles 
each consisting of 15 s at 95 °C (denaturation) and 1 min at 60 °C (annealing/extension). 
The specificity of PCR amplification was checked using a heat dissociation curve from 65°C 
to 95°C following the final cycle.  Delta Ct values (Ct) were calculated from the difference of 
the Ct of the gene of interest to the Ct of the housekeeping gene GAPDH or RPL32 and are 
shown as 1/Ct values.  
 
Sialidase activity 
Platelet sialidase activity was assessed using the 2-O-(p-Nitrophenyl)-α-D-N-
acetylneuraminic acid (Sigma) as substrate. Assays were performed in triplicate with 200µL 
of human washed platelets in Tyrode’s buffer (3.108/mL). Washed platelets were incubated 
with vehicle or 100µg/mL kE for 2 hours at 37°C together with 200µM of substrate (final 
concentration). Reactions were stopped by adding 300µL of 1M Na2CO3 and the absorbance 
of each sample was immediately measured at 405nm using an Infinite F200 PRO microplate 
reader (TECAN).  
 
 
FeCl3-induced in vivo thrombosis 
Mice were anesthetized with 25% urethane and intravenously injected with kE (10mg/kg), 
VGVAPG (40mg/kg), scrambled VVGPGA (40mg/kg) or vehicle, and rhodamine 6G (4mg/kg) 
before induction of thrombosis. Rhodamine 6G was used to label endogenous platelets and 
leukocytes. The mesenteric arteriole was isolated from surrounding tissue and spread on a 
microscopic glass. Vascular injury was performed by applying a filter paper disc (6mm 
diameter, 1mm thickness) saturated with 10% FeCl3 onto the mesenteric arteriole for 5 
minutes. After removing the filter paper, thrombus formation was monitored in real time with 
the epifluorescent microscope connected to the digital camera. Time to complete occlusion 
was defined as blood flow being stopped for at least 30 seconds.  
 
Tail bleeding time 
Bleeding time assays were performed by cutting off the tip of the tail (5mm from the tip) of 
mice anesthetized with 25% urethane and intravenously injected with kE (10 mg/kg), 
VGVAPG (40mg/kg), scrambled VVGPGA (40mg/kg) or vehicle. The tail was immediately 
immersed in saline buffer heating at 37°C. Bleeding was followed visually and time to stable 
cessation of bleeding (no rebleeding within 1 minute) was recorded. When necessary, 
bleeding was stopped manually at 15 minutes. 
 
Statistical analysis 
Results are expressed as mean +/- SEM. Two groups were compared using Student t test or 
2-tailed Mann-Whitney test. Three and more groups were compared using one-way ANOVA 
followed by Dunnett’s multiple comparison test. P values of less than 0.05 were considered 
as statistically significant. 
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